Clinical trials: completed, sponsored by Janssen Research & Development, LLC
Schizophrenia
A Study for Schizophrenia Relapse Prediction
The purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for…
- Trial name
- NCT03629951
- Testing
- Oral Antipsychotics (OAP)
- Where
- 10 sites in India
- Volunteers
- 333 people
- Sponsor
- Janssen Research & Development, LLC
Healthy Non-dependent, Recreational Sedative Users, Abuse Potential
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
The purpose of this study is to evaluate the abuse potential of seltorexant compared to placebo and two active comparators (zolpidem and suvorexant) in non-dependent, recreational sedative users.
- Trial name
- NCT05106153
- Testing
- Suvorexant, Zolpidem, Seltorexant
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women
The main objectives of this study are to determine the bioequivalence of the hormones (example, norelgestromin [NGMN] and ethinyl estradiol [EE]) from the transdermal contraceptive patch using the newly sourced adhesive component…
- Trial name
- NCT04017195
- Testing
- EVRA patch (NGMN+EE) (Treatment A) (Reference), High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
The purpose of the study is to evaluate the effect of seltorexant, compared to placebo, as an add-on medication to an antidepressant, on next-day driving performance as assessed by the mean difference of standard deviation of…
- Trial name
- NCT04451187
- Testing
- Seltorexant Dose 1, Seltorexant Dose 2, Zopiclone
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.
- Trial name
- NCT03990519
- Testing
- JNJ-26366821
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Kidney Failure, Chronic
A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function
The purpose of study is to evaluate the pharmacokinetics of a single, subcutaneous dose of JNJ-64565111 in adult participants with varying degrees of renal function including participants with end stage renal disease, requiring…
- Trial name
- NCT03546205
- Testing
- JNJ-64565111
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain
The purpose of this study is to investigate the total body biodistribution and radiation dosimetry of 11C-JNJ-63779586 by Positron Emission Tomography (PET) in healthy young adult males (Part A); to estimate and compare the…
- Trial name
- NCT03089918
- Testing
- 11C-JNJ-63779586
- Where
- 2 sites in Belgium
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Dementia, Alzheimer Disease
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
The purpose of the study is to compare the risk of dementia in participants diagnosed with rheumatoid arthritis (RA) exposed to anti-tumor necrosis factor (TNF) therapy versus those exposed to methotrexate.
- Trial name
- NCT04571697
- Testing
- Methotrexate, Anti-TNF
- Where
- United States
- Volunteers
- 34,647 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants
The primary purpose of this study is to assess the effect of ritonavir, on the single-dose pharmacokinetics (PK) of JNJ-61393215 in healthy participants.
- Trial name
- NCT03593954
- Testing
- JNJ-61393215, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants.
- Trial name
- NCT03405441
- Testing
- JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2, JNJ-55375515 Dose Level 3
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.
- Trial name
- NCT03564379
- Testing
- JNJ-42165279
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants
The purpose of this study is to characterize the plasma pharmacokinetic (PK) profile following the single ascending dose (SAD) levels of an (S)-ketamine oral solution for sublingual administration in healthy participants.
- Trial name
- NCT04282746
- Testing
- JNJ-54135419
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with…
- Trial name
- NCT05307692
- Testing
- Seltorexant
- Where
- 25 sites in United States
- Volunteers
- 88 people
- Sponsor
- Janssen Research & Development, LLC
Drug Abuse
Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users
The primary objective of this study is to evaluate the abuse potential of intranasal esketamine (112 milligram and 84 mg) compared to racemic intravenous ketamine (0.5 mg/kg) in nondependent, recreational polydrug users of…
- Trial name
- NCT02682225
- Testing
- Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy, Hepatic Impairment
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-42847922 in adult participants with hepatic impairment when compared to healthy participants with normal hepatic function.
- Trial name
- NCT04960124
- Testing
- JNJ-42847922
- Where
- 2 sites in Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-67835989 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of JNJ-67835989 versus placebo after single (or divided) oral dose administration (ascending dose levels) in healthy participants, pharmacokinetics (PK) of…
- Trial name
- NCT04844411
- Testing
- JNJ-67835989
- Where
- Belgium
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and food on the PK of single-dose of…
- Trial name
- NCT04223349
- Testing
- JNJ-70033093
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
The purpose of this study is to evaluate the pharmacokinetic (PK) and bioequivalence (BE) of ustekinumab administered by a single subcutaneous (SC) injection with Device 1 or Device 2 in healthy participants.
- Trial name
- NCT04816513
- Testing
- Ustekinumab
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of JNJ-61393215 after multiple consecutive dose administrations and to characterize the pharmacokinetics (PK) of JNJ-61393215 in plasma after multiple…
- Trial name
- NCT03007693
- Testing
- JNJ-61393215
- Where
- Netherlands
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Uterine Hemorrhage
A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants
The purpose of this study is assess the: (a) incidence of severe uterine bleeding (SUB) following exposure to individual direct oral anticoagulant (DOACs) (rivaroxaban, apixaban, dabigatran) and warfarin, (b) individual DOACs…
- Trial name
- NCT04394234
- Testing
- Direct oral anticoagulant (DOACs), Warfarin
- Where
- United States
- Volunteers
- 961,985 people
- Sponsor
- Janssen Research & Development, LLC